The Effect of Varenicline on D2/D3 Receptor Binding in Smokers

Completed 8 enrolled Centre for Addiction and Mental Health Ontario Lung Association · collab Pfizer · collab

NaSingle-groupOpen-labelBasic science

Summary

This study will evaluate effects of treatment with varenicline, a smoking cessation drug, on the dopaminergic system by using Positron Emission Tomography (PET) imaging with new radioligand, \[11C\]-(+)-PHNO. The investigators primary hypothesis is that chronic varenicline administration will increase dopamine (DA) receptors levels (\[11C\](+)PHNO) within the human brain.

Timeline

Start: 2012-09
Primary completion: 2015-08
Completion: 2015-08

Publications

Results Di Ciano P, Guranda M, Lagzdins D, Tyndale RF, Gamaleddin I, Selby P, Boileau I, Le Foll B. Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study. Neuropsychopharmacology. 2016 May;41(6):1513-20. doi: 10.1038/npp.2015.305. Epub 2015 Oct 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Varenicline	Small molecule	2 mg	—

The Effect of Varenicline on D2/D3 Receptor Binding in Smokers

Summary

Timeline

Publications

Drugs

Indications